On Friday, Shares of Altera Corp. (NASDAQ:ALTR), surged 1.55% to $44.02.
Altera Corporation, declared it will hold a conference call for interested members of the investment community at 1:45 pm Pacific Time on Thursday, April 23, 2015 to talk about the company’s first quarter results and business outlook. The company will release earnings after the market closes on April 23, 2015.
Altera Corporation, a semiconductor company, designs and sells programmable logic devices (PLDs), HardCopy application-specific integrated circuit (ASIC) devices, power system-on-chip devices (PowerSoCs), pre-defined design building blocks, and associated development tools.
Shares of OGE Energy Corp. (NYSE:OGE), gained 1.43% to $32.67, during its last trading session.
OGE Energy, will hold its quarterly conference call to talk about 1st quarter 2015 results at 9 a.m. Eastern Time (8 a.m. Central Time), Thursday, May 7, 2015.
This call is being webcast by NASDAQ OMX and can be accessed at OGE Energy’s website at www.oge.com.
OGE Energy Corp., together with its auxiliaries, operates as an energy and energy services provider that offers physical delivery and related services for electricity and natural gas primarily in the south central United States.
At the end of Friday’s trade, Shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), gained 1.41% to $84.65.
Pacira Pharmaceuticals, declared that it received a subpoena from the U.S. Department of Justice, U.S. Attorney’s Office for the District of New Jersey, requiring the production of a broad range of documents pertaining to marketing and promotional practices related to the product EXPAREL® (bupivacaine liposome injectable suspension). Pacira intends to cooperate with the government’s investigation.
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States.
Finally, Boston Scientific Corporation (NYSE:BSX), ended its last trade with 1.32% gain, and closed at $18.40.
Boston Scientific Corporation, is taking a new approach to evaluate the performance of the Vessix™ Renal Denervation System, initiating a study with a novel design to isolate the effects of the therapy in patients with high blood pressure, a silent cardiovascular killer affecting millions of people worldwide.
The first patient in the REDUCE-HTN: REINFORCE study was enrolled this week at Cardiology P.C. at Princeton Baptist Medical Center in Birmingham, Ala. by Farrell Mendelsohn, M.D., site principal investigator, and referred by Michael Wilensky, M.D. Boston Scientific received an investigational device exemption (IDE) for the study from the Food & Drug Administration (FDA) in December.
REDUCE-HTN: REINFORCE is a randomized, sham-controlled, multicenter study designed to isolate and demonstrate the effects of the Vessix™ Renal Denervation System by minimizing variability and factors that may have affected results in a competitive technology trial last year. Similar to pharmaceutical early effectiveness studies, patients in the study will undergo a four-week washout period preceding to enrollment in which they will stop taking all hypertension medications.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
